Actively Recruiting
Evaluating Docetaxel Chemotherapy After Radiotherapy for Localized High-Grade Prostate Cancer in a Multi-center Study
Led by Peking University First Hospital · Updated on 2026-08-20
315
Participants Needed
3
Research Sites
313 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effect of adding docetaxel chemotherapy after radical radiotherapy in patients with localized high-grade prostate cancer. This study focuses on men with prostate cancer confirmed by biopsy or surgery, specifically those with a Gleason score of 9-10 or containing Gleason 5 components, without distant metastasis. The goal is to understand whether adjuvant chemotherapy improves survival outcomes compared to standard treatment alone. Participants will be split into two groups one group receives standard radical treatment, which includes radiotherapy or surgery and may include endocrine therapy for high-risk patients, while the other group receives the same standard treatment followed by four to six cycles of docetaxel chemotherapy starting 4 to 8 weeks after radiotherapy. In certain cases with significant neuroendocrine differentiation and good tolerance, a combination of docetaxel and carboplatin may be used, with dexamethasone given beforehand to reduce side effects. During the study, participants will be monitored for survival outcomes including Failure-Free Survival, Biochemical Relapse-Free Survival, Metastasis-Free Survival, and Overall Survival over a five-year period. Researchers will also assess adverse events throughout this time. The study involves regular clinical assessments and imaging to confirm absence of metastasis and evaluate treatment effects, with total participation lasting several years to capture long-term outcomes.
CONDITIONS
Brief Title
Adjuvant Chemotherapy for High Malignant Prostate Cancer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here